Data Research, Vol. 1, Issue 1, Dec  2017, Pages 19-28; DOI: 10.31058/ 10.31058/

Predicting the Effect of Prolonged Dihydrotestosterone and Estradiol Valerate Administration on Male Albino Rats

Data Research, Vol. 1, Issue 1, Dec  2017, Pages 19-28.

DOI: 10.31058/

Acha, Chigozie K 1* , Udochukwu Ahaiwe 2

1 Department of Statistics, Michael Okpara University of Agriculture Umudike, Abia State,Nigeria

2 Department of Biochemistry, Michael Okpara University of Agriculture Umudike, Abia State, Nigeria

Received: 30 November 2017; Accepted: 2 January 2018; Published: 15 January 2018

Download PDF | Views 456 | Download 274


Benign Prostatic Hyperplasia (BPH) can be chemically induced in male albino rat using a combination of dihydrotestosterone (DHT) and estradiol valerate (ESV). This paper predicts the effect of BHP induction on body weight and prostrate weight of male albino rats. The study used a primary data set of ten male albino rats divided into two groups of five rats each. Group 1 (Test) was administered subcutaneous injection of DHT and ESV dissolved in olive oil once in every two days for 28 days while Group 2 (control) was administered subcutaneous injection of olive oil without DHT and ESV once in every two days for 28 days. The rats were weighed daily and histochemical examination of the prostate was carried out to ascertain the presence of BPH. The result shows that the regression coefficients of the body weight and prostrate weight have positive relationship with BPH and also highly significant at 5% level. This study highlights the predictive potentials of body weight changes as a non-assay marker for BPH in male Wister rat and all the variables are highly statistically significant (p < 0.05). The R –squared and the coefficient of determination are 74.92% and 68% respectively, indicating how much of the total variation in the dependent variable, Benign Prostatic Hyperplasia (BPH) , can be explained by the independent variables Mean Prostrate Weight and Mean Body Weight Test. Also the body weight and the prostate weight prediction result shows that they are statistically significant to BPH, their correlation result established that they are also inversely proportional.


Dihydrotestosterone, Estradiol Valerate, Prostrate, Body Weight, Regression Model


© 2017 by the authors. Licensee International Technology and Science Press Limited. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


[1] Acha, C.K. Comparative Analysis of Quadratic and Cubic Models on Egg Production. Animal Production Research Advances, 2011, 7(2), 110-115.
[2] Acha, C.K. Regression and Principal Component Analyses: A Comparison Using Few Regressors. American Journal of Mathematics and Statistics, 2012, 2(1), 1-5.
[3] Ahaiwe, U.E.; Ijeh, I.I.; Ejike C. Methanol extract of Vernonia amygdalina may protect against experimental benign prostatic hyperplasia in an albino Wistar rat model. J. Med. and Arom. plant sci. 2013, (3-4), 115-120.
[4] Anesetti G.; Chávez-Genaro R. Neonatal testosterone exposure induces early development of follicular cysts followed by sympathetic ovarian hyperinnervation. Reprod Fertil Dev. 2015, 28(11), 1753-1761.
[5] Anesetti G.; Chávez-Genaro R. Ovarian follicular dynamics after aromatizable or non aromatizable neonatal androgenization. J Mol Histol. 2016, 47(5), 491-501.
Available online: (accessed on 30 November 2017).
[6] Barry, S.J.; Coffey, D.S.; Walsh, D.C.; Ewing, L.L. The development of human benign prostatic hyperplasia with age. J Urol. 1984, 132(3), 474-497.
[7] Caldwell A.S.L.; Edwards M.C.; Desai R.; Jimenez M., Gilchrist R.B.; Handelsman D.J.; Walters K.A. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. Proc Natl Acad Sci U S A. 2017, 114(16), 3334-3343.
[8] Carlos, J.; Almeida, Flavio. Residual Urinary Volume and Urinary Tract Infection- when are they linked? The Journal of Urology, 2008, 180 (1), 182-185.
[9] Chang R.J., Cook-Andersen H. Disordered follicle development. Mol Cell Endocrinol. 2013, 373(1-2), 51-60.
[10] Clinical guideline [CG97]. Lower urinary tract symptoms in men: management. NICE (National Institute for Health and Care Excellence), 2015.
Available online: (accessed on 30 November 2017).
[11] Ejike, C.C.E.; Ezeanyika, L.U.S. Management of experimental benign prostatict hyperplasia in rats using a food-based therapy containing Telfairia occidentalis seed. Afri. J. Tradit. Compl. Altern. Med. 2010, 8(4), 398-404.
[12] Lamb, D.J.; Zhang, L. Challenges in prostate cancer research: Animal models for nutritional studies of chemoprevention and disease progression. International conference on diet, nutrition and cancer. J. Nutr. 2005, 135(12), 3009S-3015S.
[13] Matsumoto T.; Sakari M.; Okada M.; Yokoyama A.; Takahashi S.; Kouzmenko A.; Kato S. The androgen receptor in health and disease. Annu Rev Physiol. 2013, 75(13), 201-224.
[14] Morales-ledesma, L.; Ramos, J.A.D.; Hernandez, A.T. Polycystic Ovary Syndrome induced by Exposure to Testosterone Propionate and effects of Sympathectomy on the Persistence if the Syndrome. Reprod Biol Endocrinol. 2017; 15(50), 1-10.
[15] Prizant H.; Gleicher N.; Sen A. Androgen Actions in the Ovary: Balance is Key. J Endocrinol. 2014, 222(3), 141-151.
[16] Prostate Enlargement (Benign Prostatic Hyperplasia). NIDDK. September 2014. Archived from the original on 4 October 2017. Retrieved 19 October 2017.
[17] Robinson, J. Post-micturition dribble in men: causes and treatment. Nurs Stand. 2008, 22 (30), 43-46.
[18] Roehrborn, C.G. Benign prostatic hyperplasia: An overview. Rev. Urol. 2005, 7 (Suppl 9), S3-S14.
[19] Roehrborn, C.G.; McConnell, J.D. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasi In: Walsh, P. C., Retik, A. W. and Vaugh, E. (eds). Campbell’s Urology. Philadelphia Linpincot Williams and Wilkins, 2002, 1297-1336.
[20] Rosenberg, B. Metabolic control and disease. W. B. Saunders Company, 1980, 1563.
[21] Rosenfield R.L.; Ehrmann D.A. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2017, 37(5), 467-520.
[22] Sarma, A.V.; Wei, J.T. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012, 367(3), 248-257.
[23] Sotomayor-Zárate R.; Tiszavari M.; Cruz G.; Lara H.E. Neonatal exposure to single doses of estradiol or testosterone programs ovarian follicular development-modified hypothalamic neurotransmitters and causes polycystic ovary during adulthood in the rat. Fertil Steril. 2011, 96(6), 1490-1496.
[24] Uchida S. Sympathetic regulation of estradiol secretion from the ovary. Auton Neurosci. 2015, 187, 27-35.
[25] Urge incontinence. MedlinePlus. US National Library of Medicine. Archived from the original on 6 October 2015. Retrieved 26 October 2015.
Available online: (accessed on 6 November 2017).
[26] Urination - painful. MedlinePlus. US National Library of Medicine. Archived from the original on 6 October 2015. Retrieved 26 October 2015.
Available online: (accessed on 30 November 2017)
[27] White, J.M.; OBrien, D.P.; Walker, H.K.; Hall, W.D.; Hurst, J.W. Incontinence and Stream Abnormalities, Butterworths, Boston, 1990, PMID 21250138.
[28] Wu, C.P.; Gu, F.L. The prostate in eunuchs. Prog Clin Biol Res. 1991, 370, 249-55.

Related Articles